Cemiplimab-rwlc is available as Libtayo as a 350 mg/7 mL (50 mg/mL) solution in a single-dose vial for intravenous infusion. Administer Libtayo as an intravenous infusion over 30 minutes after dilution. Metastatic and locally advanced CSCC and BCC: 350 mg every 3 weeks until disease progression, unacceptable toxicity, or up to 24 months.
Day: July 29, 2026
Categories
Join YouTube Premium
Categories
Join YouTube Premium
Categories
Math Calculator
Categories
Math Calculator
Categories
